^
    Back
    Association details:
    Biomarker:MSI-H/dMMR
    Cancer:Endometrial Cancer
    Drug:Zynyz (retifanlimab-dlwr) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

    Excerpt:
    ...Tumor tissue tested as MSI-High...
    Trial ID:
    POD1UM-204
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors

    Excerpt:
    ...Patients enrolled to Cohort H (endometrial cancer 500 mg Q4W) must have MSI-H or dMMR endometrial cancer, as determined by a local laboratory using IHC or PCR methods and must also have tissue (fresh or archival) available for central confirmation of diagnosis...
    Trial ID:
    POD1UM-101
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)

    Excerpt:
    ...Group A only: Tumor tissue centrally tested as MSI-H.6. ...
    Trial ID:
    2020-000496-20
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2023
    Title:

    755P - Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H)

    Published date:
    10/16/2023
    Excerpt:
    The overall response rate by ICR was 43% (95% CI: 32–55)….Retifanlimab has shown notable clinical activity in previously treated MSI-H or dMMR endometrial cancer, which is consistent with other checkpoint immunotherapies.
    Trial ID:
    POD1UM-101
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    SITC 2020
    Title:

    268 A phase 1 study of retifanlimab (INCMGA00012), a PD-1 inhibitor, in patients with advanced solid tumors: preliminary results in recurrent MSI-high or dMMR endometrial cancer (POD1UM-101)

    Published date:
    11/09/2020
    Excerpt:
    Retifanlimab was generally well tolerated with preliminary evidence of encouraging antitumor activity in MSI-H pretreated advanced endometrial cancer.
    DOI:
    10.1136/jitc-2020-SITC2020.0268
    Trial ID:
    POD1UM-101